Robert Snyder, MD, is board-certified in dermatology and internal medicine, currently with Riverchase Dermatology.

Robert Snyder, MD

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting. 

Expert Perspectives: Dermatology's Top Story to Watch in 2025

Although nearly all medical professionals can point to a “flagship” meeting or annual conference for their specialty, few serve the same role as or measure up to what the 

American Academy of Dermatology annual meeting

A testament to the draw and magnitude of the AAD’s annual showcase, the 2025 annual meeting, which was held in Orlando, Florida, from March 07-11, 2025, had more than 20,000 registered attendees. In addition to being the field’s largest meeting, one of the unique aspects of the AAD annual meeting is its placement on the calendar. While many organizations opt for end of year or mid-year meetings, the AAD annual meeting typically occurs in Q1 and, for many, sets the tone for the remainder of the year.

With this in mind, the editorial team of HCPLive Dermatology included a simple question on the end of our interviews from the meeting with 9 leading subject matter experts in dermatology: “What is going to be the most important storyline to watch for dermatology for the rest of 2025?”

In the above video, we highlight the perspectives of these experts. Below, you can find a brief summary of the backgrounds and expertise of each individual included in this feature video.

, is a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. She also serves as president of the American Academy of Dermatology.

, is chairman at Innovaderm Research. He is also the principal investigator of the ICONIC-LEAD trial, which was presented at AAD 2025.

, is a dermatologist and internal medicine specialist with Riverchase Dermatology.

, is an associate professor of Dermatology for the USC Keck School of Medicine. She is the founding director of the USC Skin of Color and Pigmentary Disorders Program and also the president of the Skin of Color Society.

, is the owner of Medical Dermatology Specialists, chief of inpatient dermatology at BannerHealth, and the founder of US Dermatology Partners.

, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

, is an associate professor in dermatology at the Yale School of Medicine.

, is the director of the Advanced Acne Therapeutics Clinic at the Brigham and Women’s Hospital and the co-chair of the American Academy of Dermatology Acne Guidelines Work Group.

, is vice chair of research in dermatology at the Icahn School of Medicine at Mount Sinai and director of the Mark Lebwohl Center for Neuroinflammation and Sensation.

Videos

2025 American Academy of Dermatology (AAD) Annual Meeting

 in Orlando, remibrutinib’s positive impact on sleep and daily activities among patients with chronic spontaneous urticaria (CSU) was highlighted.

Remibrutinib—an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor that is in development for individuals suffering from CSU—was studied in the phase 3 REMIX 1 and 2 multicenter, double-blind, randomized trials. To discuss the biggest takeaways, Robert Snyder, MD, an investigator who works with Riverchase Dermatology, spoke with 

Remibrutinib Impacts on Sleep, Daily Activities in CSU up to Week 52, with Robert Snyder, MD

“So this was two phase 3 trials, REMIX 1 and 2,” Snyder said. “Identical trials in which patients were randomized to receive 2 to 1 remibrutinib or placebo at the dose of 25 milligrams BID, with primary endpoints measured at 12 weeks and there was continued observation of responses at 24 weeks and up to 52 weeks. At 24 weeks, the placebo arm was transitioned to remibrutinib to examine the response, and the primary endpoint was here Urticaria Activity Score. Secondary endpoints and exploratory endpoints were examined.”

At the 1, 12, 24, and 52-week mark, Snyder and his team of investigators looked into the mean change from baseline (CFB) ± standard deviation in participants’ weekly Sleep/Activity Interference Scores (SIS7/AIS7) as well as proportions of those showing a complete lack of disease interference on their Sleep/Activity (SIS7=0/AIS7=0).

“My abstract that was presented at the meeting today had to do with the improvement in sleep deprivation and daily activity that are important components of the disease burden for patients with CSU,” Snyder explained. “So I'll start by saying there was a rapid response in terms of differentiating the improvement in sleep deprivation between placebo seen as early as 1 week.”

Snyder highlighted that there was progressive improvement through Week 24 as well as maintenance of improvement through Week 24. He noted that the high level of response of no impact on sleep and daily activity, which was the aim with treatment, was observed in 6 out of 10 patients at Week 24. This was maintained to the 52-week mark.

“I think the the key takeaway is this is a novel oral medication that has the potential to become a go-to therapy for patients who are second generation anti-histamine resistant,” Snyder said. “The current paradigm of treatment suggests treating patients with anti-histamines at maximized doses before moving on to systemic therapies.”

For additional information on Snyder’s research, view the full video interview posted above. To learn more about data presented at AAD 2025, view our 

The quotes used in this video summary were edited for the purposes of clarity. Snyder is a speaker and/or advisor for and/or has received research funding from Janssen Biotech, Amgen, Novartis, BMS, Galderma, AbbVie, Leo Pharma, Sun Pharma, Regeneron, Sanofi, Pfizer, and UCB.

Snyder R, Bin Y, Metz M, et al. Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria (CSU) up to Week 52 in the REMIX-1/-2 studies. Presented at the 2025 American Academy of Dermatology (ADA) Annual Meeting. Orlando, FL. March 07-11, 2025.

This interview with Snyder features a discussion on recent findings on remibrutinib among patients with chronic spontaneous urticaria, also known as CSU.

Robert Snyder, MD

Articles